PC
TVGN icon

Periscope Capital’s Tevogen Bio Holdings TVGN Stock Holding History

Periscope Capital’s Portfolio TVGN Stock Details TVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,492
Closed -$5.94M – 805
2022
Q4 		$5.94M Sell
11,492
-10
-0.1% -$5.12K 0.26% 149
2022
Q3 		$5.83M Sell
11,502
-3,406
-23% -$1.72M 0.17% 244
2022
Q2 		$7.46M Hold
14,908
– – 0.2% 190
2022
Q1 		$7.45M Buy
+14,908
New +$7.41M 0.19% 189

Other funds holding TVGN

CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Periscope Capital's TVGN Position: Q1 2023 in Review

Periscope Capital sold out of Tevogen Bio Holdings (TVGN) in Q1 2023, closing a stake of 11,492 shares — an estimated $5.94M sold.

Periscope Capital first reported a position in TVGN in Q1 2022 and held it in 4 quarters. The position peaked at $7.46M in Q2 2022. 4 funds tracked by Wall St. Rank hold TVGN as of Q1 2023.

  • Periscope Capital reported no remaining Tevogen Bio Holdings position as of Q1 2023 after selling out during the quarter.
  • Periscope Capital sold 11,492 Tevogen Bio Holdings shares in Q1 2023, an estimated $5.94M.
  • Periscope Capital first reported a position in Tevogen Bio Holdings in Q1 2022 and held it in 4 quarters.
  • Periscope Capital's Tevogen Bio Holdings position peaked at $7.46M in Q2 2022.
  • 4 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q1 2023.

Based on Periscope Capital's 13F filing for Q1 2023, filed 12 May 2023.